Baird Financial Group Inc. Sells 155,943 Shares of Kenvue Inc. $KVUE

Key Points

• Baird Financial Group Inc. has reduced its stake in Kenvue Inc. by 18.1% in Q1, now holding 705,974 shares valued at approximately $16.93 million.
• Institutional investors collectively own 97.64% of Kenvue's stock, with notable increases in stakes from several firms, including Vanguard Group Inc. and JPMorgan Chase & Co..
• Kenvue recently declared a quarterly dividend of $0.2075 per share, reflecting a slight increase from the previous dividend, thereby establishing a 4.0% dividend yield.

Baird Financial Group Inc. cut its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 18.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 705,974 shares of the company's stock after selling 155,943 shares during the quarter. Baird Financial Group Inc.'s holdings in Kenvue were worth $16,929,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Mercer Global Advisors Inc. ADV grew its position in Kenvue by 23.9% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 50,329 shares of the company's stock worth $1,075,000 after buying an additional 9,714 shares in the last quarter. AXA S.A. grew its position in Kenvue by 75.6% during the fourth quarter. AXA S.A. now owns 35,954 shares of the company's stock worth $768,000 after buying an additional 15,479 shares in the last quarter. Aptus Capital Advisors LLC acquired a new stake in Kenvue during the fourth quarter worth about $206,000. Ameriprise Financial Inc. lifted its stake in Kenvue by 8.9% during the fourth quarter. Ameriprise Financial Inc. now owns 5,010,382 shares of the company's stock worth $106,972,000 after purchasing an additional 408,127 shares during the period. Finally, Cary Street Partners Financial LLC bought a new position in Kenvue during the fourth quarter worth about $270,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE:KVUE traded down $1.91 during trading on Friday, reaching $18.64. The stock had a trading volume of 135,326,130 shares, compared to its average volume of 13,801,933. Kenvue Inc. has a 52 week low of $17.15 and a 52 week high of $25.17. The business's 50-day moving average price is $21.37 and its 200 day moving average price is $22.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The stock has a market capitalization of $35.76 billion, a PE ratio of 25.18, a P/E/G ratio of 2.95 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. Kenvue's quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. This is an increase from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio is presently 112.16%.

Analyst Ratings Changes

KVUE has been the subject of a number of analyst reports. UBS Group cut their price target on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Citigroup cut their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Royal Bank Of Canada cut their price target on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Finally, Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Kenvue presently has an average rating of "Hold" and a consensus target price of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.